REG - Creo Medical Group - Positive Q1 trading update

Creo MedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260422:nRSV3903Ba&default-theme=true

RNS Number : 3903B  Creo Medical Group PLC  22 April 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

Positive Q1 trading update

 

Strong trading momentum continues with 60% year-on-year revenue growth in Q1

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, provides a trading update for the three months ended 31 March
2026 (Q1 FY26).

 

Further to the update
(https://www.creomedical.com/en/investors/regulatory-updates) provided on 20
January 2026, the Company's growth momentum for the year ended 31 December
2025 (FY25) has continued, with a strong trading performance in Q1 FY26.
Year-on-year revenue growth (Q1 FY26 vs Q1 FY25) was c.60%, the upper limit of
management's expectations. This performance underpins management's view that
the Company is on track to deliver 40% to 60% full year revenue growth during
FY 2026.

 

Along with top line growth, management continues to focus on improving the
operational efficiency of the business. Following the announcement of the sale
and outsourcing of its manufacturing operations
(https://www.londonstockexchange.com/news-article/CREO/disposal-and-outsourcing-of-manufacturing/17549211)
announced on 16 April 2026, the Company is expected to reduce underlying
operating costs by 15% compared to FY25 on an annualised basis.  Commercial
progress continues to be made across the Company's product portfolio,
supported by excellent clinical validation.

 

Creo's full year results for 2025 are expected to be announced in May 2026.

 

For further information please contact:

 

 Creo Medical Group plc                                                         www.creomedical.com
                                                                                (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                              Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser)         +44 (0)20 7260 1000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                                   +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                       Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFFILSFILFIR



            Copyright 2019 Regulatory News Service, all rights reserved